Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Resolute Forest Products Inc. (RFP) on Thursday reported a loss of $45 million in its fourth quarter.
http://www.cnbc.com/2017/02/02/the-associated-press-resolute-forest-products-posts-4q-loss.html
Resolute Forest Products (RFP) Misses Q4 EPS by 12c
Resolute Forest Products (NYSE: RFP) reported Q4 EPS of ($0.03), $0.12 worse than the analyst estimate of $0.09. Revenue for the quarter came in at $889 million versus the consensus estimate of $905 million.
For earnings history and earnings-rel
http://www.streetinsider.com/Earnings/Resolute+Forest+Products+(RFP)+Misses+Q4+EPS+by+12c/12489825.html
In trading on Thursday, shares of Resolute Forest Products Inc (TSX: RFP. O) crossed below their 200 day moving average of $6.83, changing hands as low as $5.54 per share.
https://www.thestreet.com/story/13976729/1/notable-two-hundred-day-moving-average-cross--rfp.html
Resolute Forest Products Inc. (NYSE:RFP) (TSE:RFP) released its quarterly earnings data on Thursday. The company reported ($0.03) earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.09 by $0.12. The company had revenue of $889 million for the quarter, compared to analysts’ expectations of $905 million. Resolute Forest Products had a negative net margin of 7.04% and a negative return on equity of 0.98%. The business’s quarterly revenue was down .6% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.29) EPS.
https://baseballnewssource.com/markets/resolute-forest-products-inc-rfp-releases-earnings-results/397692.html
Corium International, Inc. just filed a prospectus, suggesting it plans to soon issue some securities
We estimate that the net proceeds of this offering, after deducting underwriting discounts and commissions and estimated offering expenses, will be approximately $18.5 million, or $21.4 million if the underwriter’s option to purchase additional shares is exercised in full.
http://www.conferencecalltranscripts.org/PROS/summary/?id=3441275
Corium Internation (CORI) Prices 6.67M Shares at $3
http://www.streetinsider.com/Equity+Offerings/Corium+Internation+(CORI)+Prices+6.67M+Shares+at+$3/12490269.html
Stemline says patient died during Phase 2 BPDCN trial
On January 18, the company received a report that a patient death had occurred. The patient had developed capillary leak syndrome, a known, sometimes fatal, and well-documented side effect of SL-401
http://thefly.com/landingPageNews.php?id=2499112&headline=STML-Stemline-says-patient-died-during-Phase--BPDCN-trial
Shares of Stemline Therapeutics (NASDAQ:STML) tumbled nearly 37% this morning after investors learned that a patient died in a clinical trial involving its lead drug candidate, SL-401. The news was not reported by the company, but confirmed by the patient's family and first reported by Adam Feuerstein of TheStreet.
Not hearing the news directly from management is bad enough, but the death occurred the day before a Jan. 19 stock offering for $45 million. Worse still, this is the third death to occur in a clinical trial involving SL-401 from a side effect known as capillary leak syndrome, a form of low blood pressure. The company had responded to previous patient deaths by altering dosing regimens, so the recent death hints that the drug may not be safe enough for human use in its current form or dosing.
Safety concerns now seem likely to derail an otherwise effective drug candidate -- an increasingly common theme for next-generation immunotherapy treatments. As Feuerstein writes, in earlier clinical trials "SL-401 has demonstrated robust overall tumor response rates of 84%, including 56% complete or near-complete response in patients enrolled in its clinical trial." The company had previously expected to use phase 2 results to obtain marketing approval for the drug candidate, but that now could be in doubt.
https://www.fool.com/investing/2017/02/02/heres-why-stemline-therapeutics-stock-fell-369-thi.aspx
Side Effect Kills Cancer Patient in Stemline Therapeutics Drug Trial; Company Raises Money
https://www.thestreet.com/story/13975695/1/side-effect-kills-cancer-patient-in-stemline-therapeutics-drug-trial-the-company-raises-money.html
OPTIONS TRADERS PLACE FRESH BETS ON SPIRALING SEADRILL LTD (SDRL) STOCK
http://www.schaeffersresearch.com/content/options/2017/01/31/options-traders-place-fresh-bets-on-spiraling-seadrill-ltd-sdrl-stock
Seadrill Limited (Bermuda) (SDRL) Moves Lower on Volume Spike for January 31
eadrill Limited (Bermuda) (SDRL) traded on unusually high volume on Jan. 31, as the stock lost 29.7% to close at $1.87. On the day, Seadrill Limited (Bermuda) saw 50.25 million shares trade hands on 55,003 trades. Considering that the stock averages only a daily volume of 8.87 million shares a day over the last month, this represents a pretty significant bump in volume over the norm.
Generally speaking, when a stock experiences a sudden spike in trading volume, it may be seen as a bullish signal for investors. An increase in volume means more market awareness for the company, potentially setting up a more meaningful move in stock price. The added volume also provides a level of support and stability for price advances.
https://www.equities.com/news/seadrill-limited-bermuda-sdrl-moves-lower-on-volume-spike-for-january-31
The key aims of the Company`s restructuring continue to be building a bridge to a recovery and achieving a sustainable capital structure. Based on these considerations, the Company projected that this be achieved by:
1. Extending bank maturities to mature in the period from 2021 to 2023, reducing fixed amortization and amending financial covenants;
2. Extending the maturity of unsecured claims to mature in the period from 2025 to 2028; and
3. Raising at least $1.0 billion in new capital.
The Company is targeting reaching a contract on a consensual, comprehensive restructuring before the maturity of the West Eminence facility on April 30, 2017. Assuming we achieve this target, we expect the implementation of a contract to occur during the second quarter of 2017. We are also actively preparing various contingency plans in the event we do not reach a consensual agreement.
Per Wullf, CEO and President of Seadrill Administration Ltd. comments: “These negotiations have proved to be more complex than we had originally anticipated. Nevertheless, key stakeholders have demonstrated a clear desire to be part of a solution and with the right structure and terms we believe there is noteworthycapital available to us. Seadrill is a great company with excellent people, assets and customers and we look forward to concluding a transaction that ensures Seadrill continues to be well positioned for the eventual recovery in the industry.”
http://wallstrt24.com/stocks-trend-analysis-report-seadrill-ltd-nysesdrl-sanchez-energy-corp-nysesn/2428222/
http://shortsqueeze.com/?symbol=SDRL
SDRL short interest 90,416,000. days to cover 9.8
what is the reason for this surge. Anybody no any good new? I searched google,yahoo no news found.
EnteroMedics Inc. has 1 year price target of $140. The stock gained a consensus recommendation of 1 on Zacks Investment Research where the scale runs from 1 to 5, 1 representing Strong buy and 5 showing Strong Sell
https://topchronicle.com/enteromedics-inc-nasdaqetrm-fell-36-85/
Pulmatrix's CEO Eyes $25 Billion COPD Market for Its Inhaled Drug Delivery Technology
http://finance.yahoo.com/news/pulmatrixs-ceo-eyes-25-billion-143200309.html
Pulmatrix Receives Patents Important to its Inhaled Drug Delivery Technology
LEXINGTON, Mass., Dec. 19, 2016 /PRNewswire/ -- Pulmatrix, Inc. (PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has received five patents over the last 12 months
http://finance.yahoo.com/news/pulmatrix-receives-patents-important-inhaled-145000650.html
Currently, many CF patients experience allergic reactions when their lungs become infected with a fungus called Aspergillus. Doctors now try to treat those infections with oral drugs such as itraconazole. Oral antifungals require very high doses to get enough of the drug to the lungs through the bloodstream to fight the fungus, causing severe side effects, and oral antifungals are not always effective. Pulmatrix's goal is to solve this problem by combining itraconazole with its innovative dry powder iSPERSE™ technology. "By delivering the drug directly to the lungs, we should be able to fight the infection far more effectively than the oral drug can, with far fewer side effects," explained Pulmatrix's Chief Scientific Officer, David L. Hava, PhD. "That should bring great benefits to patients."
Pulmatrix, Inc. (PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that its drug candidate for treating fungal infections in the lungs of CF patients, PUR1900, has been designated as a "Qualified Infectious Disease Product" (QIDP) by the U.S. Food & Drug Administration.
Under the QIDP program, which is designed to speed the development of novel drugs against important pathogens, Pulmatrix will receive five years of additional market exclusivity for PUR1900.
http://finance.yahoo.com/news/pulmatrix-drug-candidate-receives-qualified-144500653.html
Pulmatrix Inc. (PULM) announced Tuesday morning that the FDA has designated PUR1900, its drug candidate for treating fungal infections in the lungs of CF patients, as a "Qualified Infectious Disease Product."
Pulmatrix climbed for the bulk of the morning Tuesday and finished with a gain of 0.87 at $1.55 on the highest volume of the year. The stock surged to over a 2 1/2 month high.
http://www.rttnews.com/2733864/pulmatrix-inc-pulm-leaped-to-over-a-2-month-high-on-fda-news.aspx
http://postregistrar.com/2017/01/12/overbuying-stock-in-the-spotlight-biocept-inc-nasdaqbioc/
Overbuying Stock in the Spotlight: Biocept Inc
Biocept Inc (NASDAQ:BIOC) share price soared 49.72% or +0.90 points to reach at $2.71 during previous trading session. The stock’s price fluctuated within the range of $2.10 – $3.39 during previous trading session. A total of 62,916,599 shares exchanged hands, whereas the company’s average trading volume stands at 1.64M shares. Biocept Inc (NASDAQ:BIOC) has a market capitalization of $84.15M and most recently 17.50M outstanding shares have been calculated.
In terms of Buy/Sell recommendations, analysts have a consensus rating of 2.00 on the shares of Biocept Inc (NASDAQ:BIOC). Out of rating recommendations 0 have given the stock a Buy while 2 recommend the stock as Outperform. 0 have given the stock a Hold rating, 0 as Underperform and 0 as Sell.
When we have a peek on stock’s historical trends we come to know that, the stock has climbed 226.51% in the past one week and soared 204.49% during previous one month drive, the stock went up 99.56% during past quarter. In the last six months the stock’s performance soared 330.16% while yearly performance of the company advanced 68.32%. The company’s year to date (YTD) performance is at 249.68%.
While taking a glance at financials, we can look at a number of key indicators. Biocept Inc (NASDAQ:BIOC) has a Return on Assets (ROA) of -279.40%. The company currently has a Return on Investment (ROI) of -390.80%. Average true range (ATR-14) of the company sets at 0.23, along with its weekly and monthly volatility of 33.64%, 13.51% respectively.
The company’s quick ratio for most recent quarter is 0.30 along with current ratio for most recent quarter of 0.30.
What Wall Street is saying about Biocept, Inc. (NASDAQ:BIOC)
iocept, Inc. (NASDAQ:BIOC) stock is presently standing at about $2.71 and lots of equity research firms seem to have a target price set on the stock. And a quick view of analyst notes show that 0 are rating the stock a buy while 0 rate BIOC a strong buy. There are 0 equity research firms advocating a Hold and 0 consider it Sell.
http://theindependentrepublic.com/2017/01/12/what-wall-street-is-saying-about-biocept-inc-nasdaqbioc/
Biocept Announces In-Network Agreement with Blue Cross Blue Shield of Illinois
More than eight million members gain access to Biocept's suite of blood-based diagnostics through agreement with Illinois' largest health plan, bringing total covered lives to approximately 133 million.
"BCBS IL is the largest health plan in Illinois and is our first agreement with a plan in the Blue Cross Blue Shield system," said Michael W. Nall, President and CEO of Biocept. "We view this agreement as another indication of the growing awareness by healthcare providers of the important role liquid biopsy can have in the treatment of patients with cancer. For Biocept, gaining health plan coverage for our tests is a key aspect of our reimbursement strategy."
"For a significant number of patients with cancer, obtaining sufficient biopsy material from a surgical procedure is neither possible nor practical. By utilizing liquid biopsy, physicians can gain valuable information for use in developing treatment plans for their patients," said Amy McNeal, Senior Director of Strategic Reimbursement at Biocept. "Our goals at Biocept and the payor community are aligned as we work together to improve patient outcomes while providing savings to the healthcare system."
http://www.prnewswire.com/news-releases/biocept-announces-in-network-agreement-with-blue-cross-blue-shield-of-illinois-300201642.html
anyone has insight about the today's price direction of fnma?
HHGregg, Inc. (HGG) Upgraded to “Hold” by Zacks Investment Research
http://zolmax.com/investing/hhgregg-inc-hgg-upgraded-to-hold-by-zacks-investment-research/1145046.html
HHGregg, Inc. (HGG) Upgraded to “Hold” by Zacks Investment Research
http://zolmax.com/investing/hhgregg-inc-hgg-upgraded-to-hold-by-zacks-investment-research/1145046.html
The three-card Monte accounting of Fannie, Freddie conservatorship
Admittedly partisan study raises troubling questions
Treasury justified the conservatorship of the GSEs via accounting gimmicks since they faced no liquidity issue at the time of the crisis and recession. They note that Fannie Mae’s Cash Net Income, adjusted for non-cash items, was positive throughout entire crisis and recession.
In the third quarter of 2008, the financials should have looked like an abattoir floor. But it didn’t.
If, the authors argue, the GSEs were on the verge of diabetic coma and they needed their insulin from Treasury, they’d be stone cold dead.
So how did Fannie or Freddie keep operations going while they were supposedly insolvent?
The answer is simple: they were never insolvent…the smoke and mirrors of accounting reserves were used to make them appear that way.
Loan loss and FMV reserves were materially overstated in 2008 and 2009 then reversed in 2013 and beyond.
Rep and Warrant accounting was incorrect. Never recorded any receivable from the banks, only impaired the defaulted loan
If everything in the whole report – and I urge you to look the full thing, with its extensive research and footnoting – then there’s an amazing amount of gymnastics you have to go through to get to where the Treasury stands today.
The Deferred Tax Asset Reserve should have never been booked in the first place. Using the uncertainty of conservatorship as a reason to impair while ignoring the previous 18 years of profitability is unreasonable and incorrect. On the flip side, ignoring the uncertainty of conservatorship in 2013 to reverse the reserve is cherry picking and also incorrect.
What they’re saying – and I can’t find a good counterargument otherwise – is that the Treasury can’t use the argument to its advantage on the front end and ignore its existence on the back end.
Deloitte knew or should have known better…and they should be on the hook for the cost of a full restatement. In addition, all non-cash inflated reserves that were historically unnecessary must be reversed and pushed back into Net Income. Deloitte simply has no margin for error based on Treasury’s imposed “Net Asset” trigger for borrowing funds.
http://www.housingwire.com/blogs/1-rewired/post/34280-the-three-card-monte-accounting-of-fannie-freddie-conservatorship
A key Trump donor could make a ton of money from Trump's housing policy
Trump adviser John Paulson is heavily invested in Fannie and Freddie
Paulson was listed as one of Trump’s economic advisers during the 2016 campaign. And as the Intercept has noted, Trump’s July 2015 financial disclosure form showed him with more than $1 million invested in each of three Paulson funds: Paulson Partners LP, Paulson Advantage Plus LP, and Paulson Credit Opportunities LP.
That’s significant because Paulson hedge funds appear to have a significant stake in Fannie and Freddie. Paulson and Company, the company that manages all three of the funds Trump was invested in last year, has been lobbying the federal government to change how it manages the two companies, which are still under federal stewardship.
Paulson and several other hedge fund moguls are objecting to a 2012 decision to redirect Fannie and Freddie’s profits into the federal treasury — instead of paying them out as dividends to shareholders like Paulson
http://www.vox.com/new-money/2016/12/6/13843760/trump-paulson-fannie-freddie
no opinion released today
http://finance.yahoo.com/news/sallie-mae-went-private-fannie-161053603.html
How Sallie Mae Went Private, And How Fannie Mae And Freddie Mac Could Do The Same
Mnuchin didn’t provide details about the game plan for Fannie and Freddie, but some analysts have speculated that the Trump administration intends to allow the two government-sponsored enterprises (GSE) retain their profits and enter the private market. That could put Fannie and Freddie on the same path that student lender SML Corp(NASDAQ: SLM) took.
i do not that. he disclosed his information for the election reason and that is where from i gave you the snippet.
we should have been heard by now. But because of the political reason they are not releasing opinion for now. I believe they want to wait for new administration to take office. So you now 90% of the dc circuit opinion is sided with the government. they are in a wait and see mode to know the new administration's view on fnma and fmcc.
Trump’s treasury pick gives hedgies 12 billion reasons to smile
Hedgies invested in Fannie Mae and Freddie Mac unwrapped an early $12 billion
That’s how much value was added to the mortgage giants’ shares after Trump’s treasury secretary-designee, Steven Mnuchin, said one of his priorities was to “get Fannie and Freddie out of government ownership.”
“It makes no sense that these are owned by the government and have been controlled by the government for as long as they have,” the 53-year-old former Goldman Sachs partner told Fox Business Network.
Investors took Mnuchin’s comments to mean the Treasury Department would stop collecting the profits of the two companies — as it has since taxpayers came through with a $187.5 billion bailout in 2008.
Hedge fund moguls have been pressing that point for years.
http://nypost.com/2016/12/01/trumps-treasury-pick-gives-hedgies-12b-reasons-to-smile/
Treasury Nominee Mnuchin Promising on Volcker Rule and Fannie and Freddie
Mnuchin is correct that Fannie Mae and Freddie Mac have been in the government-run conservatorship for too long and should be released into the private sector. Yet this release must be done in a way that both respects Fannie and Freddie shareholder rights and gets rid of any explicit or implicit government backing of the two entities
https://cei.org/blog/treasury-nominee-mnuchin-promising-volcker-rule-and-fannie-and-freddie
http://www.fidererongses.com/params/post/1030318/the-187-billion-fannie-freddie-bailout-is-a-big-half-lie
The big half-lie about the $187 billion bailout, like the big lie about private-gains/public-losses, leaves the false impression that Fannie and Freddie operated a failed business model and/or they were mismanaged. These two deceptions are also used to attack lawsuits alleging that the government’s decision, to drain all cash and equity out of both companies in perpetuity to make sure that preferred and common shareholders never recover a nickel, was illegal.
trumps holding of fnma assets
http://stocktwits.com/symbol/FNMA?q=FNMA
Treasury Secretary Steve Mnuchin Confirms New ParadigmIn a few sentences on Fox Business News newly announced Treasury Secretary Steve Mnuchin confirmed what until now had been backroom whispers and innuendos.He turned the eight-year logjam on GSE reform upside down.
If you have not seen this please take a moment now and see for yourself if you have seen it watch it again, this is the single biggest development in our cause to date. Start at 04:55. “We’ve got to get Fannie and Freddie out of government ownership. It makes no sense that these are owned by the government and have been controlled by the government for as long as they have.” – Steven Mnuchin
http://video.foxbusiness.com/v/5229369696001/?#sp=show-clips
Because there have already been serious discussions about the GSE issue within Team Trump Mnuchin was well prepared for the question. As I said earlier, there are members including John Paulson on the team who are deeply knowledgeable and quickly separate facts from the false hype. The fact that Mnuchin stated that they would get this done quickly also confirms that the wheels are already in motion to bring about the end of both the sweep and conservatorship of Fannie and Freddie. Essentially Steve confirmed the main points we had heard coming out of Trump’s camp when he said that by having the government boot on Fannie and Freddie’s necks has greatly hampered the housing recovery. It has kept out private capital and forced millions of home buyers onto the sidelines.
https://timhoward717.com/2016/12/01/treasury-secretary-steve-mnuchin-rocks-the-world-declares-fannie-and-freddie-will-be-freed/
Carl Icahn Joins Bill Ackman In Bet On Fannie And Freddie
Carl Icahn appears to have joined the hedge fund party that is trying to make a fortune off of the resuscitation of mortgage giants Fannie Mae and Freddie Mac, the government sponsored enterprises that were bailed out during the financial crisis and placed into conservatorship.
Icahn took a $50 million position in Fannie Mae and Feddie Mac in March by buying common stock from Bruce Berkowitz’s Fairholme Funds. Icahn bought 6.8 million shares of Fannie Mae for $4.03 per share and 5.7 million shares of Freddie Mac for $4.04 per share, according to a court document that was reported by The Wall Street Journal and CNBC. Berkowtiz, who bet early and big on Fannie and Freddie, not only gets to book a nice gain on the shares he sold to Icahn, but he potentially also gets an ally in his effort to make outsized gains from his continued large position in both the common and preferred shares of the GSEs
http://www.forbes.com/sites/nathanvardi/2014/06/03/carl-icahn-joins-bill-ackman-in-bet-on-fannie-and-freddie/#7f623b93326b
Settling the Fannie Freddie Fiasco: Steven Mnuchin Reverse the Obama Administration Scorched Earth Litigation Strategy If They Hope to Privatize Fannie and Freddie
http://www.forbes.com/sites/richardepstein/2016/12/02/settling-the-fannie-freddie-fiasco-steven-mnuchin-reverse-the-obama-administration-scorched-earth-litigation-strategy-if-they-hope-to-privatize-fannie-and-freddie/2/#4004b1b32ea4
Fannie/Freddie investor deal sooner rather than later - Dick Bove
Corporate tax cuts would produce negative net worths for Fannie Mae (OTCQB:FNMA -6.6%) and Freddie Mac (OTCQB:FMCC -5.9%) as it would reduce the value of their DTAs, says Rafferty Capital's Dick Bove. Thus, incoming Treasury Secretary Steven Mnuchin will need to hammer out a deal with investors prior to any tax bill.
Mnuchin, says Bove, understands the GSEs as well as anyone thanks to his experience turning around IndyMac. "If there's anyone in the U.S. who can do it, it’s the guy who solved IndyMac."
He believes it's possible Mnuchin has already held talks with Trump supporter and Fannie investor John Paulson, and that other prominent investors like Bruce Berkowitz and Bill Ackman would prefer a quick deal vs. spending years and millions in court.
On Jan. 20, all the material Democrats have withheld from the courts becomes available to the Trump administration, says Bove. This gives Mnuchin "staggering leverage" against potential Democratic opposition.
Source: Bloomberg
http://seekingalpha.com/news/3228329-fannie-freddie-investor-deal-sooner-rather-later-dick-bove?app=1&uprof=17&utoken=351e26c06a6d141cee435fb3e66db33b4a657848#email_link
Trump Treasury May Mean Independence for Fannie and Freddie
So what might happen now? In his comments, Mr. Mnuchin nodded to a crucial issue regarding Fannie and Freddie: safety and soundness. “We’ll make sure that when they’re restructured, they’re absolutely safe and they don’t get taken over again,” he said, “But we got to get them out of government control.”
A first step in ensuring that Fannie and Freddie are safe would be to let them rebuild their capital. Since the government began taking all their profits in 2012, it has directed the companies to operate on a small and shrinking sliver of capital. Under the current arrangement, the companies will have zero capital at the end of 2018.
This is clearly untenable and unsafe for taxpayers, who would again be on the hook if Fannie and Freddie began losing money.
An easy way to let them rebuild capital would be to end the quarterly transfer of all their profits to the Treasury. This would not require legislation; it could be done administratively with incoming Treasury officials advising the Federal Housing Finance Agency, which regulates Fannie and Freddie, to change the terms of the government’s agreement with the companies. This was supposed to happen anyway while the companies were operating under the conservatorship.
http://www.nytimes.com/2016/12/02/business/trump-treasury-may-mean-independence-for-fannie-and-freddie.html?_r=0
not at all. you will find out in about a few days. you may have to buy it for 5 dollars/share again.